Blood pressure is an important cardiovascular risk factor 1 , with estimated 30-50% heritability 2, 3 . Over the past several years, genomewide association studies (GWAS) have identified 85 SNPs associated with blood pressure [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . However, the heritability explained remains less than that for other quantitative cardiovascular traits, for example, lipids 23 . Three strategies to identify additional variants are the use of larger sample sizes, more precise measurements, and more extensive imputation panels. Thus far, all large studies have used measurements from research protocols rather than clinical records. There is little doubt that the phenotype seen in observational research or randomized trials is similar to that in a clinical encounter, but clinical measures may be influenced by somewhat different circumstances and measurements may be obtained under a less stringent protocol 24 . However, studies using clinical measurements from electronic health records (EHRs) permit not only very large sample sizes but also a long-term average of multiple independent clinical measurements from many different clinical visits, yielding reduced phenotype variance (as shown by simulation and experimental data) 7 . We therefore reasoned that a large-sample blood pressure GWAS with longitudinal EHR-based measures would provide improved statistical power and understanding of blood pressure genomic architecture, which we show theoretically (Online Methods) and through data application.
(DBP) were highest in African Americans, followed by non-Hispanic whites; South Asians had lower values (Fig. 2) . Untreated blood pressure measures were higher in males than in females across the groups, as also found previously 25 .
To further investigate covariate effects, we assessed the effects of age, sex, BMI, and genetic ancestry on SBP, DBP, and pulse pressure (PP) within each ancestry group ( Supplementary Table 1 ). Age and age 2 accounted for substantial variation in SBP, as expected, with the Replication test in ICBP + UKB ( Fig. 3a) ICBP + UKB meta-analysis GERA + ICBP metaanalysis -36 additional novel SNPs (Fig. 3b) Replication test in UKB (Fig. 3b Figs. 1-4) . In addition to the linear regression analytic approach used in previous GWAS 13, 14, 17 , we used a mixedmodel approach that yielded slightly smaller λ values, suggesting improved adjustment for population substructure and/or cryptic relatedness ( Supplementary Table 2 ). We detected 75 independent genome-wide significant (P ≤ 5 × 10 −8 ) loci associated with one or more blood pressure phenotypes (Supplementary Figs. 1-4 and Supplementary Tables 1-5) .
Of the 75 identified loci, 36 replicated previous GWAS findings. Of the remaining 39 new loci ( Fig. 3) , 25 were strictly replicated (P ≤ 0.00067, Bonferroni correction for 75 = 39 + 36 SNPs; Online Methods) in 221,477 individuals from ICBP (HapMap summary statistics augmented with 1000 Genomes Project data; Online Methods and Supplementary Fig. 5 ) 17 and UKB (imputed additionally using UK10K 27 ). Of the 14 remaining loci, 8 had suggestive significance (P ≤ 0.01) and 1 X-chromosome SNP was unavailable for replication. All SNPs with at least suggestive significance (P ≤ 0.05) had effects in the same direction as in GERA and had no significant heterogeneity among the GERA ancestry groups or between GERA, ICBP, and/or UKB ( Fig. 3 and Supplementary Table 3 ), giving further credibility to the notion that these loci are also true positive findings. Of note, ICBP alone poorly replicated new SNPs (only three SNPs met significance with Bonferroni correction in ICBP alone), although the SNPs were highly enriched for small P values. These results emphasize the importance of large replication cohorts.
Expanding our discovery to a meta-analysis of GERA and ICBP also did not indicate significant inflation (average λ = 1.042; Supplementary Table 2 ); this λ value is slightly smaller than for GERA alone, likely owing to the slightly conservative nature of extending the ICBP summary statistics (Online Methods). Thirty-six additional new loci reached genome-wide significance for at least one blood pressure phenotype. Using 152,081 individuals from UKB for replication, 22 loci replicated at P ≤ 0.00067 (Bonferroni correction for 75 SNPs), 7 were suggestive with P < 0.01, and 2 reached nominal significance (P < 0.05). As before, all SNPs with at least nominal significance (P < 0.05) had the same direction of effect in UKB, arguing for a low rate of false positive findings ( Fig. 4 and Supplementary Table 3 ). We did not detect significant heterogeneity for any lead SNP.
Finally, to maximize discovery power, we combined all three studies (GERA, ICBP, and UKB; n = 321,262). Our genome-wide meta-analyses of SBP, DBP, and PP had λ values of 1.069, 1.076, and 1.076, respectively. We identified 241 additional new genomewide significant loci ( Supplementary Fig. 6 and Supplementary  Table 3 ), although replication was not possible. Only rs139491786 showed evidence of heterogeneity (I 2 = 88, P = 1.5 × 10 −5 ).
Conditional analysis
We first searched for additional genome-wide significant SNPs within a 1-Mb window (±0.5 Mb with respect to the lead SNP) involving each previously described or new locus in GERA, testing for replication in UKB. We first identified an additional new SNP, rs1322640, 129 kb from rs13197550 (lead GERA SNP) that replicated in UKB (P = 8.3 × 10 −6 ; Table 2 and Supplementary Table 5 ). We next identified a new indel (chromosome 20, 10,573,001 (Build 37)) located 396 kb from rs2104574 (lead GERA SNP) that replicated in UKB (P = 0.012; Table 2 and Supplementary Table 5 ).
We further combined GERA and UKB in a discovery conditional meta-analysis, identifying four additional independent signals ( Table 2 and Supplementary Table 5 ). No replication was possible for these.
Replication of previous GWAS results
We also investigated replication of previously described blood pressure loci in GERA (Supplementary Table 6 , which also reports the GERA lead SNP when it differs from the previously described lead SNP at the locus) [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Of the 85 previously described lead SNPs (or a proxy with r 2 = 1.00 for one SNP), 62.4% (53/85) were significantly associated with at least one GERA blood pressure phenotype A r t i c l e s 
Effect size Effect size Effect size Figure 3 New blood pressure loci detected in GERA and tested for replication in ICBP + UKB meta-analysis. SNPs rs76217164 and rs143118162 failed to impute in ICBP (owing to low allele frequency), and rs141216986 was on the X chromosome and not available in ICBP or UKB. We used an additive model. The effect allele is the allele to the left (for example, A in A/G). Effect sizes are indicated in mm Hg. Each line represents the effect size and its 95% confidence interval for each measure and group, with the text beside each line denoting the group tested: G, GERA (n = 99,785); IU, meta-analysis of ICBP and UKB (n = 221,477); and GIU, meta-analysis of GERA, ICBP, and UKB (n = 321,262). The color of each line corresponds to the statistical significance of the test: red, P ≤ 1 × 10 −9 ; orange, 1 × 10 −9 < P ≤ 5 × 10 −8 ; green, 5 × 10 −8 < P ≤ 0.00067 (Bonferroni correction for 39 + 36 = 75 SNPs); blue, 0.00066 < P ≤ 0.05; black, P > 0.05. If a SNP is in a gene, that gene is given; otherwise, the two surrounding genes are given.
A r t i c l e s at P < 0.00059 (with Bonferroni adjustment for 85 tests) and had the same direction of effect; 78.8% (67/85) were nominally significant; and 95.3% (81/85) had effects in the same direction. Replication was stronger in UKB, with 77.6% (66/85) replicating at Bonferroni significance, 89.4% (76/85) replicating at nominal significance, and 96.5% (82/85) having effects in the same direction. Replication was Figure 4 New blood pressure loci identified in the GERA + ICBP meta-analysis and tested for replication in UKB. We used an additive model. The effect allele is the allele to the left (for example, A in A/G). Effect sizes are indicated in mm Hg. Each line represents the effect size and its 95% confidence interval for each measure and group, with the text beside each line denoting the group tested: GI, meta-analysis of GERA and ICBP (n = 169,181); U, UKB (n = 152,081); and GIU, meta-analysis of GERA, ICBP, and UKB (n = 321,262). The color of each line corresponds to the statistical significance of the test: red, P ≤ 1 × 10 −9 ; orange, 1 × 10 −9 < P ≤ 5 × 10 −8 ; green, 5 × 10 −8 < P ≤ 0.00067 (Bonferroni correction for 39 + 36 = 75 SNPs); blue, 0.00066 < P ≤ 0.05; black, P > 0.05. If a SNP is in a gene, that gene is given; otherwise, the two surrounding genes are given.
further improved in meta-analysis of the GERA and UKB cohorts, where 84.7% (72/85) met Bonferroni-adjusted significance, 89.4% (76/85) were nominally significant, and 96.5% (82/85) had effects in the same direction. In addition, testing an aggregate, weighted genetic risk score (GRS) using all 85 previously described SNPs for each blood pressure trait led to highly significant associations in all GERA ancestry groups, with P < 1 × 10 −168 (whites), P < 1 × 10 −22 (Latinos), P < 1 × 10 −9 (East Asians), P < 0.002 (African Americans), and P < 1 × 10 −350 in UKB whites, for all blood pressure traits ( Table 3 ). In GERA, Latinos had a larger mean SBP GRS than whites (P = 0.053), whereas African Americans had a lower one (P = 0.032). When GERA African Americans were stratified by European ancestry, SBP GRSs were lower in individuals with 0-50% European ancestry (coefficient = 0.65, 95% confidence interval (CI) = 0.18-1.13) than they were in those with 50-100% European ancestry (coefficient = 1.04, 95% CI = 0.56-1.51), although these confidence intervals overlap. The same trend appeared for DBP and PP ( Table 3 ). There was also a very high degree of concordance for the estimated regression coefficients for SBP, DBP, and PP among the non-Hispanic whites in GERA, ICBP, and UKB (Supplementary Fig. 7) .
When examining the effects of individual SNPs, we found that SNPs discovered in ICBP typically had weaker effects than those discovered in GERA, likely owing to winner's curse 28 . The opposite was also the case: SNPs discovered in GERA had weaker effects in ICBP. UKB comparisons were similar, with SNPs having stronger effect sizes in the discovery cohort (GERA or GERA + ICBP) than in the replication cohort (UKB). Seven SNPs exhibited significant heterogeneity among studies (P < 0.00059, with Bonferroni correction for 85 SNPs) at the lead trait ( Supplementary Table 6 ).
Variance explained and gain using multiple blood pressure measurements
The variance explained in an additive linear model by the 75 genomewide significant loci identified in our GERA discovery cohort was 1.4%, 1.2%, and 1.8% for SBP, DBP, and PP, respectively, in GERA non-Hispanic whites; note that the same individuals were used for discovery and testing, but with the independent ICBP estimated effect sizes. The results for each measure in the other GERA groups were as follows: 2.0%, 1.6%, and 2.4% in Latinos; 0.9%, 0.7%, and 1.4% in East Asians; 1.3%, 0.6%, and 1.6% in African Americans; and 1.7%, 1.7%, and 0.7% in South Asians. Including the remaining SNPs out of the 85 previously described ones that were not genome-wide significant in GERA and the 36 new SNPs from the GERA + ICBP meta-analysis modestly increased the variance explained ( Table 3) . All previously described and new loci explained 2.9%, 2.5%, and 3.1% of the variation in SBP, DBP, and PP in GERA non-Hispanic whites, respectively, with estimated greater (but not significantly different) variance explained in Latinos (3.4%, 2.6%, and 3.6%) and less variance explained in East Asians (2.4%, 1.7%, and 2.6%) and African Americans (2.0%, 1.3%, and 2.1%), who similarly had the lowest GRSs. UKB results were generally slightly lower than those A r t i c l e s for GERA: for example, 2.7%, 2.5%, and 3.0% for UKB whites. Adding dominance terms to the linear regression model did not increase the variance explained (none significant after multiplecomparison correction).
We subsequently investigated the impact of multiple blood pressure measurements in an analysis restricted to individuals who had ≥5 measurements (Supplementary Fig. 8 ). Using all measurements, in comparison to just one, reduced the regression coefficient standard 
Blood pressure risk scores and onset of hypertension
We tested the association of the GRSs (described above for SBP, DBP, and PP) with time to onset of hypertension. The predictive value of the GRSs increased with the number of blood pressure-associated SNPs included (Table 3) , as expected. When including SNPs from the meta-analysis of all three cohorts, the SBP GRS was the strongest predictor of hypertension, with a hazards ratio (HR) in non-Hispanic whites of 1.18 (P = 8.2 × 10 −45 ); the DBP GRS was slightly less significant with HR = 1.14 (P = 1.3 × 10 −30 ), as was the GRS for PP with HR = 1.15 (P = 1.5 × 10 −33 ). The GRSs were also predictive in other ancestry groups: for example, the significance for the SBP GRS was P = 1.4 × 10 −6 in Latinos, P = 0.0021 in East Asians, and P = 0.00024 in African Americans.
Sex differences
We tested for differences in SNP effect size by sex (heterogeneity test; Supplementary Table 8 ; coefficients plot in Supplementary Fig. 9 ). After Bonferroni correction (α = 0.00013, including all 386 new and previously described SNPs), no SNP showed a significantly difference in effect size between the sexes. However, 25 SNPs had a nominally significant (P < 0.05) difference for the lead trait, which is in slight excess of the 19.3 SNPs expected; of the SNPs with the same direction of effect in males and females, 17 of 20 (85.0%, 95% CI = 61.1-96.0%) had effects of stronger magnitude in females than in males.
Differences in SBP, DBP, and PP effects
We tested whether the normalized effect size of each SNP was greater for SBP or DBP (Online Methods and Supplementary 
eQTL analysis in different tissues
We investigated whether the previously identified and all new loci colocalized with expression quantitative trait loci (eQTLs). We used eQTLs from 44 Genotype-Tissue Expression (GTEx) tissues and kidney 32, 33 . Across all tissues, 186 of the 367 sentinel SNPs were eQTLs in at least one tissue; at least one SNP in 213 of the same 367 loci was an eQTL. We determined for each tissue whether the number of eQTLs (identified by either sentinel SNP or locus) was greater than expected by chance, where expectation was derived from a random sampling of SNPs and loci (Online Methods). We ranked the tissues by eQTL P value, for both the sentinel SNP and locus analyses. We generally expect tissues with more eQTLs to overlap more SNP sets and enrichment to be greater simply because of chance GWAS set overlap, especially when eQTLs in tissues relevant to the phenotype are also found in these tissues. To observe whether the enrichment visible for a given tissue was greater than expected relative to the total number of eQTLs the tissue contained, we examined the relationship between P value and total eQTL count for each tissue (Fig. 5) . The aorta and tibial artery were clear outliers in comparison to other tissues, even when accounting for the total number of eQTLs.
Enrichment analysis for functional elements
We subsequently investigated whether genes near sentinel variants were enriched for certain functional pathways. We included genes within ±0.5 Mb of the 390 sentinel variants with a significant eQTL in either aorta or tibial artery. We identified 2,013 genes near all A r t i c l e s 390 sentinel variants (Online Methods) and tested for enrichment of functional annotation. Using DAVID 6.8 (refs. 34,35) , 1,480 of these genes had annotations, yielding 26 significant annotation terms (Benjamini-Hochberg P < 0.05; Supplementary Table 10 ), but no clear functional pathway emerged.
DISCUSSION
In this large, ancestrally diverse GERA cohort with EHR-derived blood pressure measures, we discovered 39 new genome-wide significant blood pressure loci, most of which replicated in ICBP and UKB. Merging GERA and ICBP identified 36 additional new genome-wide significant loci, most of which replicated in UKB. Finally, merging all three cohorts identified 241 additional genome-wide significant loci, although no replication was available. Conversely, we were able to replicate almost all 85 previously described blood pressureassociated SNPs. We also showed that using multiple EHR blood pressure measurements almost doubled the variance explained, although the total variance explained remains small (for example, 2.9% for SBP in non-Hispanic whites). We also showed that blood pressure signals are enriched in two large arteries, the aorta and tibial artery.
Our study used a large general population sample with EHR-derived data for the first time, to our knowledge, in blood pressure GWAS. The consistency and generalizability of blood pressure genomics findings from one-time research-protocol-based assessments to purely clinical measures recorded in an EHR have been questioned 36 . We were able to replicate most previously identified loci from many cohorts using research-based assessments, demonstrating that blood pressure genetic findings are not significantly different between studies using research assessments and those using clinical, EHR-derived ones. This is important because clinical measures recorded in the EHR are the basis for clinical decisions in general, real-world clinical practice. Moreover, this extends the reach of GWAS to numerous clinical samples.
EHR-based studies offer additional benefits. Our identification of new variants takes advantage of multiple independent measurements in the EHR to increase statistical power 7 . Our study increased the standardization and reduced the variability of the EHR-derived blood pressure measures by excluding measures obtained in clinical settings with increased measurement variability, for example, emergency rooms, and retaining measures obtained in visits to primary care/internal medicine departments.
The new blood pressure-associated SNPs identified have similar genomic contexts to those previously described, of which 8.2%, 20.0%, 32.9%, and 38.8% were located in exons, UTRs, introns, and intergenic regions, respectively; the new SNPs identified in GERA were distributed with 2.6%, 23.1%, 33.3%, and 41.0% in these regions, those from the GERA and ICBP meta-analysis had a distribution of 0%, 2.8%, 55.6%, and 41.7%, and those from the GERA, ICBP, and UKB meta-analysis had a distribution of 2.5%, 14.9%, 41.5%, and 41.1% (Supplementary Table 4) 37 . The frequencies and variant types of the lead SNPs are also similar to those previously described; for individuals of European ancestry, 85.9% of previously described SNPs have minor allele frequencies (MAFs) >0.10, in comparison to 89.7% of GERA-identified SNPs, 94.4% of SNPs identified by GERA and ICBP meta-analysis, and 82.2% of SNPs identified by GERA, ICBP, and UKB meta-analysis. When comparing results across traits within GERA, the leading trait locus was more often associated with PP for new loci than before (24.7% of previously described SNPs were associated with PP versus 59.0%, 58.3%, and 41.9% in GERA, GERA + ICBP, and GERA + ICBP + UKB, respectively); this may reflect the fact that earlier blood pressure studies tested SBP and DBP, but not PP. We additionally demonstrate the significant effect of summary blood pressure SNP scores on time to onset of hypertension, enabled by GERA longitudinal EHR data. We note that a GERA hypertension GWAS produced no additional novel results (and yielded results much less significant than those for the continuous blood pressure traits, as expected).
One limitation was that 1000 Genomes Project-imputed results were unavailable in ICBP; however, the much larger UKB replication cohort did not have this limitation. For ICBP, we therefore relied on imputation of summary test statistics using HapMap. Use of these approximated results, and the fact that all test statistics from ICBP were based on SNP results imperfectly imputed to HapMap data, likely led to diminished effect sizes in ICBP. Overall, we needed a very large number of individuals for replication, in both the replication of our new GERA results, which improved greatly when adding UKB to ICBP, and the replication of previously described results, which improved when adding UKB to GERA.
Another advantage of a single large cohort, such as GERA, is the ability to directly assess additional local SNPs by conditional analysis. The absence of individual-level data requires assumptions about linkage disequilibrium (LD) from other studies. Nevertheless, we only found two additional variants in GERA that were ultimately not explained by nearby previously described SNPs, and an additional four when combining GERA and UKB. We further note that these additional conditional hits were located at a substantial distance from the sentinel SNP of the locus, likely indicating an independent gene and/or mechanism involved. The lack of identification of additional SNPs close to sentinel SNPs is quite distinct from what is observed for serum lipids, for example 38 , and suggests that lowerfrequency variants with larger effects within the same loci identified here are uncommon. A similar conclusion was recently obtained in a sequencing study of type 2 diabetes 39 .
Although our sample sizes were smaller in the other ancestry groups than they were for non-Hispanic whites, we noticed that Latinos had the highest standardized GRS, followed closely by non-Hispanic whites and then by East Asians and African Americans. In African Americans, European ancestry was associated with lower blood pressure, but individuals with more European ancestry had higher standardized blood pressure GRSs (created from previously described SNPs); this observation is counterintuitive but may reflect the fact that the GWAS discovery occurred primarily in Europeanancestry individuals, and it suggests that there may be other SNPs in African Americans remaining to be identified.
We also looked for a pattern in terms of which loci replicated. Logically, the largest replication indicator was discovery P value, as stronger associations likely require a smaller sample size for replication than weaker ones. In GERA, loci with P ≤ 1 × 10 −9 replicated at a Bonferroni level at a rate of 76.5% (13/17) versus a rate of 54.5% (12/22) for loci with 5 × 10 −8 ≤ P < 1 × 10 −9 ; all of the ICBP SNPs with P ≤ 1 × 10 −9 replicated at a Bonferroni level in GERA + UKB; however, this pattern was not seen in the GERA and ICBP meta-analysis, where 57.1% (4/7) of the loci with P ≤ 1 × 10 −9 versus 62.1% (18/29) of the loci with 5 × 10 −8 ≤ P < 1 × 10 −9 replicated, although numbers were small. Perhaps also of note, the two SNPs in GERA with MAF <0.001 failed to replicate in UKB (P > 0.05).
We also searched for eQTL enrichment in a variety of tissues. Both aorta and tibial artery were clear outliers in comparison to other tissues, suggesting that genetic factors influencing vascular elasticity and/or stiffness are important determinants of blood pressure and hypertension.
There are several reasons for the enhanced discovery in our study: increased sample size, multiple blood pressure measures (reducing phenotype variability), better designed arrays with increased genomic coverage 40, 41 , and larger imputation reference panels (reducing error and providing additional imputed SNPs). We observed a 25% reduction in SNP effect standard error when using multiple blood pressure measurements. In addition, 15 SNPs not present in the 1000 Genomes Project were genome-wide significant in the UKB data alone (6.2% of the 241 new SNPs), while none of the SNPs in the 1000 Genomes Project surrounding them met genome-wide significance.
After completion of our analyses, three additional large-scale blood pressure/hypertension GWAS were published [42] [43] [44] , including, as in our study, hundreds of thousands of individuals in discovery and replication phases. Notable among the findings were an enrichment of SNPs also involved in cardiometabolic traits 42 and the implication of genetic variation in vascular function 42, 44 , as we also found. Two of the studies 42,43 also focused on rare variation and identified a few rare missense and nonsense variants of larger effect in eight distinct genes. These studies collectively identified 71 distinct new genome-wide significant loci. Using a broad definition of overlap (r 2 > 0.3), a cursory examination suggests that 16 of these loci overlap with our 316 new hits (2 of the 39 from GERA alone, 4 of the 36 from GERA + ICBP, and 10 of the 241 from GERA + ICBP + UKB). These studies, along with ours, demonstrate the enhanced power of both gene discovery and characterization afforded by expanded sample sizes.
In summary, the current study demonstrates the utility of a large general cohort with multiple independent EHR-derived measurements for studying blood pressure genetics; it is reassuring that the same blood pressure loci found in research-based cohorts are captured with high significance and also that the longitudinal data typical for EHRs provide important opportunities for new SNP discovery. The new SNPs found here may provide novel mechanistic insight into the control and treatment of hypertension, ultimately preventing a variety of clinical sequelae.
URLs. UK Biobank, http://www.biobank.ac.uk/; Kaiser Permanente Research Bank portal, http://researchbank.kaiserpermanente.org/forresearchers/.
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weight and height (21,001.0.0). Sex was determined genetically (22,001.0.0). Analysis was carried out as in GERA, a meta-analysis of each self-reported ancestry group (21,000.0-2.0): we identified 145,341 individuals who reported any white group and with global ancestry PC 1 ≤ 50 and PC 2 ≤ 50, where global PC 1 and PC 2 were calculated from the entire cohort (22,009.0.1-2), including 2,274 South Asians, 2,029 African British, 1,979 mixed/other, and 458 East Asians, totaling 152,081 individuals. Ancestry principal components within whites were calculated using 50,000 random white individuals with the remaining subjects projected, which has been shown to work well 45 , and then within each other group. We analyzed 35,893,267, 12,078,001, 19,866,667, 15,820,020, and 7,298,789 SNPs with r iffo 2 ≥0.3 and MAF ≥0.0001, 0.005, 0.005, 0.005, and 0.025, in whites, South Asians, African Europeans, mixed/other, and East Asians, respectively (42,521,712 unique SNPs).
GERA meta-analysis with ICBP and with UKB. We additionally performed meta-analysis of the GERA and ICBP results for genome-wide discovery using a fixed-effects meta-analysis, with UKB for replication. We further performed a discovery meta-analysis of GERA, ICBP, and UKB for maximal discovery size but with no replication sample available. In this analysis, we reviewed the locus plots, manually merging the windows located ±0.5 Mb with respect to the SNPs when necessary. Specifically, after assessing SNPs in the GERA + ICB + UKB meta-analysis, we checked whether the SNPs appeared independent in a meta-analysis of GERA and UKB, as both had individual-level data. Most regions were either obviously correlated with high r 2 or were obviously not correlated with r 2 <0.05; however, to formalize the conditional analysis and retain a SNP as independent, we required that the reduction in P values from univariate to joint in the GERA + UKB meta-analysis be less than tenfold and additionally that translating an equivalent reduction in P values to the GERA + ICBP + UKB meta-analysis still led to a genome-wide significant result (that is, if we assumed that P joint,GERA+ICBP+UKB /P univariate,GERA+ICBP+UKB = P joint,GERA+UKB /P univariate,GERA+UKB , the approximated P joint,GERA+ICBP+UKB would still need to be genome-wide significant). This may have been slightly conservative.
Replication analysis of previously described SNPs in GERA.
To determine how many of the 85 previously described loci from ICBP and other GWAS replicated in this study, we tested the sentinel SNPs from those studies in our data set [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Frequently, multiple blood pressure phenotypes are reported for the same loci. We used Bonferroni correction for replication (85 SNPs, α = 0.00059). The SNP rs2446849 was not in our reference panel, so we used the closest proxy, rs2513758, at a physical distance of 876 bp and r 2 = 1.00 in Europeans.
GRS construction.
We constructed a GRS for each of the three blood pressure traits for each individual by summing the additive coding of each set of SNPs associated with the particular blood pressure trait weighted by the previously described effect size from ICBP and then standardized the distribution of all groups simultaneously by the mean and standard deviation (to a standard normal distribution) for interpretability. We used the leading SNP from each locus.
Multiple measurements.
To assess the impact of multiple blood pressure measurements, we compared the P value and effect size estimates for the previously described GWAS significant SNPs using one, two, three, four, and all measurements from each individual. We used a set of 67,547 non-Hispanic white individuals, all with ≥5 blood pressure measurements available for this analysis, to keep the sample size identical among comparisons. We also examined the variance explained by a GRS of the previously described hits assuming previous effect sizes as a function of the number of blood pressure measurements.
From this analysis, we can also estimate both the variance due to measurement error and variance explained by the GRS in the absence of measurement error, as follows. Let B = the observed blood pressure measurement, G = the GRS, E = the residual genetic and environmental effect on blood pressure, M = the component of blood pressure due to measurement error, and k = the number of blood pressure measurements. We assume that the measurement error is independent across multiple measures within an individual, and the additive model B = G + E + M k for the average of k blood pressure measurements. Let V B = Var(B), V G = Var(G), V E = Var(E), and V M = Var(M). For k blood pressure measurements with independent measurement error, V Mk = V M /k. The proportion H of variance in blood pressure attributable to the GRS is V G /(V G + V E + V M /k). Then, 1/H = (1 + V E /V G ) + (V M /V G )/k = α + β(1/k), where α = 1 + V E /V G and β = V M /V G . We thus have a linear model of 1/H in terms of 1/k, and 1/α = V G /(V G + V E ) is the proportion of variance due to the GRS in the absence of measurement error and β/(α + β) is the proportion of variance in blood pressure due to measurement error. Fitting a linear regression model to 1/H as a function of 1/k, we can then use the estimated intercept (α) and regression coefficient (β) to estimate the error variance and variance due to the GRS in the absence of measurement error.
Blood pressure risk scores and onset of hypertension. We additionally tested GRS constructed by weighting different subsets of identified blood pressure-associated SNPs (identified for SBP, for DBP, and for PP, constructed as described above). Hypertension onset here was defined as the first hypertension treatment time or the first time either SBP ≥140 or DBP ≥90 occurred in an individual and was maintained for the next subsequent blood pressure measurement. Individuals were left censored at their first measurement (and not included if already meeting the hypertension diagnosis criterion) and right censored at their latest measurement if not hypertensive.
Differences in SBP, DBP, and PP effects.
We also tested whether the normalized effect size of each SNP was different for SBP versus DBP. Suppose that Y is SBP normalized to a standard normal (mean centered and then divided by the standard deviation) and Z is normalized DBP and that X is the SNP dosage. Then, we model Y = aX + E and Z = bX + F, where a is the regression coefficient for Y on X and, similarly, b is the coefficient for Z; E and F are the residual errors, respectively. Since Var(Y) = Var(Z) = 1, assuming a and b have the same sign (which is generally the case because the phenotypes are correlated), testing the equality of a and b is also a test of effect difference between SBP and DBP. Now, consider the difference Y -Z = (a -b)X + (E -F).
Regressing Y -Z on X tests the difference between a and b; in this analysis, we additionally adjust for the same covariates as discussed previously.
GWAS heritability from all measured SNPs. We estimated the additive array heritability of each individual's long-term average age-and BMI-adjusted blood pressure residuals using GEAR v0.7.7 (ref. 30 ). Array heritability estimates may be more sensitive to artifacts than GWAS results 57 , so we restricted our analysis to the largest group of individuals, non-Hispanic whites, that were run with the same reagent kit and type of microarray (n = 73,133) 46 . We used only autosomal data, a common practice in array heritability estimation, and also LD filtered our data so no two pairwise SNPs had r 2 >0.8 with a standard greedy algorithm in PLINK v1.07 (ref. 58) . This resulted in 547,922 genotyped SNPs and 3,796,606 imputed SNPs restricted to r info 2 >0.8. Because of population stratification, we used PC-Relate 29 to estimate kinship coefficients rather than the standard GCTA estimates 31 , which assume a homogeneous population; we also compared the results to those obtained using the standard GCTA kinship estimates with principal-component adjustment. We used GEAR rather than GCTA to estimate heritability because the PC-Relate kinship matrix estimate was not positive definite; this can be explained by the fact that the matrix entries are computed on the basis of different allele frequencies, that is, those depending on ancestry from the principal-component analysis. In all analyses, we removed individuals so that no two remaining individuals had a kinship estimate >0.025; sample size was maximized with PLINK v1.9 (ref. 59), leaving us with 62,133 individuals. eQTL enrichment analysis. To carry out tissue-specific eQTL enrichment analysis, we used 44 tissue types with at least 70 samples available from GTEx 32 in addition to 7 kidney eQTLs 33 . We used 367 sentinel variants from previously identified SNPs and the three discovery stages presented here with MAF >0.001 and in eQTL databases. Next, 100 sets of 367 random pseudo-sentinel variants were selected matching the MAF to that of the original 367 SNPs (within ±0.5%). Within each set, the selection was done without replacement; the match for each variant was selected one at a time, and selection of the
